EGFR and pancreatic neoplasm: Among the BiXAbTM that most strongly inhibited the phosphoproteome in pancreatic cancer cells stimulated with the EGF+NRG1 ligand mix, anti-EGFR/HER3 BiXAbTM, including 3Patri-1Cetu-Fc and 3Patri-1Matu-Fc, were consistently more effective.